Beyond Flatiron: The Rising Power Of Oncology Clinical Data Companies
- Friday, March 9, 2018, 1:04
- Entrepreneurs
- Add a comment
It will behoove drug makers to anticipate real world efficacy prior to launch, as the limiting factor for commercialization could soon be not whether a drug is approved by the FDA, based on clinical trial data, but whether it’s validated by clinical data companies, based on real-world performance.
https://www.forbes.com/sites/davidshaywitz/2018/03/09/beyond-flatiron-the-rising-power-of-oncology-clinical-data-companies/
About the Author
admin123 has written 23412 stories on this site.
